The data has been re-analysed for disease-free and overall survival by means of a multivariate Cox regression analysis. Adjustment has been made for age, T stage and N stage. At the time that this study was conducted, most breast cancer diagnoses were confirmed by fine needle sample alone, and not biopsy. Therefore, no pre-chemotherapy tissue was available for assessment of histopathological features, such as grade, which impact on disease outcome [1] . Tissue taken at surgery after completion of chemotherapy was available for many patients but it is unclear whether this is an accurate reflection of pre-chemotherapy features [2] .
After multivariate analysis adjusted for T and N stage, good response remains statistically significantly related to diseasefree survival (P = 0.02) ( Fig. 1 ) and overall survival (P = 0.02) (Fig. 2 ). This does not exclude a bias due to oestrogen receptor status or grade. Furthermore, the magnitude of the difference is considerable (77% versus 63% for overall survival).
Although our study is very modest in size, unlike large multi-centre studies, it is strengthened by the fact that clinical response was assessed by a limited number of individuals. We agree that more data is needed to characterise further the relationship between response and outcome, particularly in view of the fact that the large EORTC 10902 failed to confirm this on multivariate analysis [3] . We agree that a relationship between good clinical response and favourable outcome may reflect a more favourable natural history in tumours that demonstrate good response, rather than a treatment effect. This seems unlikely in view of the fact that high base-line Ki-67 is a predictor of good clinical response [4] but a poor prognostic factor overall [5] . 
